GSK’s chief scientist says an overhaul of the drugmaker’s R&D unit has begun delivering results and pledged a tighter focus than his predecessor on infectious disease and HIV.
Posts
Analysts said the development marked a key milestone for Intellia and the broader gene editing field, as it points to FDA’s increased willingness to allow trials for gene therapies.
Aera Therapeutics emerged from stealth mode Thursday with a platform based on the work of Feng Zhang, Ph.D. and ex-Alnylam executive Akin Akinc at the helm.
Sanofi has inked a licensing deal with Scribe Therapeutics to develop novel natural killer (NK) cell therapies for cancer using Scribe’s CRISPR genome editing technology.
A study published this month in Science discusses data that may support a devious alter ego of T-cells present within colorectal cancer tumors.
DEM BioPharma, backed by an impressive list of investors, debuted Thursday with $70 million that will assist in its efforts to treat cancer with an approach that leverages CRISPR screening and macrophage biology in immuno-oncology.
